| Drug ID: | Drug103 |
|---|---|
| Drug Name: | Rifaximin |
| CID: | 6436173 |
| DrugBank ID: | DB01220 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00355602 |
| Molecular Formula: | C43H51N3O11 |
| Molecular Weight: | 785.9 g/mol |
| Isomeric SMILES: | C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C |
| Synonyms: | Rifaximin; Rifaxidin; 80621-81-4; Rifacol; Rifamycin L 105; Rifaximine; Fatroximin; Rifamixin; Rifaximina; Normix |
| Phase 0: | 4 |
| Phase 1: | 20 |
| Phase 2: | 73 |
| Phase 3: | 50 |
| Phase 4: | 32 |
| Description: | Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It is used to treat diarrhea caused by E. coli. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt880 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | None | |
| dt881 | 6436173 | Rifaximin | 93777907 | rpoB | Escherichia coli K-12 | Inhibitor | |
| dt882 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | Agonist | |
| dt883 | 6436173 | Rifaximin | 1576 | CYP3A4 | Homo sapiens (human) | Substrate|Inducer | |
| dt884 | 6436173 | Rifaximin | 1557 | CYP2C19 | Homo sapiens (human) | Inducer | |
| dt885 | 6436173 | Rifaximin | 1558 | CYP2C8 | Homo sapiens (human) | 11996015 | Inducer |
| dt886 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | 22790967 | [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CD36 protein|[nr1i2 results in increased susceptibility to rifaximin] which results in increased expression of CFD mrna|[nr1i2 results in increased susceptib |
| dt887 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | 21599020 | [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [trinitrobenzenesulfonic acid results in increased expression of TNF protein]|[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits th |
| dt888 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | Rifaximin results in increased activity of NR1I2 protein | |
| dt889 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | Rifaximin results in increased expression of NR1I2 mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NL-OMON25521 | Microbiota targeted therapy as alternative for prednisolone and biologicals in IBD patients during the current COVID-19 threat: a prospective study addressing the safety of Budesonide in combination with rifaximin or the Crohns Disease Exclusion Diet (CDED) | Not Available | No | Nestlé 23/08/2021 | None | The results of this prospective study may result … | Details |
| NCT00355602 | Antibiotics for the Treatment of Ulcerative Colitis | None | COMPLETED | University of Dundee | Colitis, Ulcerative | DRUG: Cefuroxime|DRUG: Ciprofloxacin|DRUG: Clarit… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease ac…
PMID: 20112064
Year: 2010
Relationship Type:
Treatment
Score: 6.1
AIMS: Enteric bacteria are thought to contribute to the pathogenesis of Crohn's disease, and antibiotics may be an effective therapy. This study exam…
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases
PMID: 19881343
Year: 2010
Relationship Type:
Treatment
Score: 6.1
PURPOSE OF REVIEW: Rifaximin is gaining attention for its potential activity in a multitude of gastrointestinal diseases. We review the unique pharma…
Showing 21-22 of 22 articles